Physician profile
Michele Farber
NPI 1497016596
$5,769.51
in general payments reported to CMS, 2019-2025
28 companies · $1,022 in 2025
The $1,022 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,823 · 2020: $191 · 2021: $252 · 2022: $791 · 2023: $651 · 2024: $1,040 · 2025: $1,022.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,712.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,712.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,178.28 | 2019-2025 | |
| Galderma Laboratories, L.P. | $1,120.56 | 2019-2025 | Dysport, Nemluvio |
| Incyte Corporation | $505.30 | 2022-2025 | Opzelura |
| Janssen Biotech, INC. | $430.51 | 2019-2025 | Tremfya |
| Sun Pharmaceutical Industries INC. | $364.10 | 2019-2025 | Ilumya |
| Novartis Pharmaceuticals Corporation | $346.39 | 2019-2025 | |
| Dermavant Sciences, INC. | $326.34 | 2023-2024 | Vtama |
| Regeneron Healthcare Solutions, INC. | $212.87 | 2022-2025 | Dupixent, Libtayo |
| Leo Pharma INC. | $150.14 | 2021-2025 | Adbry, Anzupgo |
| Pfizer INC. | $131.90 | 2019-2022 | |
| Mayne Pharma Commercial LLC | $109.18 | 2019-2020 | |
| Amgen INC. | $107.17 | 2023-2025 | Otezla, Otezla |
| Genzyme Corporation | $107.00 | 2022-2025 | |
| Organon LLC | $80.32 | 2025 | Nexplanon |
| Verrica Pharmaceuticals INC. | $76.80 | 2024-2025 | Ycanth |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arcutis Biotherapeutics, INC. | $70.50 | 2023-2025 | Zoryve |
| Ucb, INC. | $69.29 | 2022-2025 | Bimzelx |
| Celgene Corporation | $65.04 | 2019 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $61.99 | 2019-2020 | |
| Almirall LLC | $47.18 | 2022-2025 | Klisyri |
| Genentech USA, INC. | $39.86 | 2019 | |
| Allergan, INC. | $36.58 | 2019-2022 | |
| Botanix Sb INC | $35.90 | 2025 | Sofdra |
| Springworks Therapeutics, INC. | $22.88 | 2025 | Gomekli |
| Vyne Pharmaceuticals INC. | $21.45 | 2020 | |
| Journey Medical Corporation | $21.17 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $16.12 | 2025 | Sotyktu |
| Strata Skin Sciences, INC. | $14.69 | 2024 | Xtrac |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michele Farber listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.